Mr. Huffines joined J.P. Morgan in 1991 and is currently a Vice Chairman of Investment Banking. Mr. Huffines joined J.P. Morgan in the Mergers and Acquisitions group where he was healthcare focused. From 2002 – 2010, Mr. Huffines was co-head of the global healthcare investment banking group. In 2011, he was promoted to Vice Chairman to deepen the firm’s relationships with significant clients.

Mr. Huffines has advised numerous healthcare companies on strategic transactions, including: Medivation’s sale to Pfizer (pending); Alere’s sale to Abbott (pending); Baxter on Baxalta’s sale to Shire; Celgene1s acquisition of Receptos; Merck’s acquisition of Cubist; Boston Scientific1s acquisition of Endo’s Men’s Health business; Johnson &Johnson’s sale of Cordis and Ortho Clinical Diagnostics; Thermo Fisher’s acquisition of FEI Affymetrix and Life Technologies; Baxter’s acquisition of Gambro; Healthpoint’s sale to Smith & Nephew; Lincare’s sale to the Linde Group; Amgen acquisition of Mustafa Ncvzat; Kinetic Concepts’ go-private; Sanofi-Avcntis’ acquisition of Genzyme; Merck’s acquisition of Schering Plough; Eli Lilly’s acquisition of ChemGen; BristolMyers Squibb’s acquisition of Medarex; Celgene’s acquisition of Phannion, Kinetic Concept’s acquisition of LifeCell; Amgen’s sale of Amgen K.K. to Takeda; Eisai’s acquisition of MGI Pharmaceuticals; Takeda on its division and integration of the Takeda Abbott Products joint venture; Sirtris Pharmaceutical’s sale to Glaxo SmithKline; Guidant’s sale to Boston Scientific and Abbott; Merck’s acquisitions of Banyu Pharmaceuticals; Rosetta Inpharmatics and Pro Vantage Healthcare and divestiture of Medco Health Solutions; Bristol-Myers Squibb’s divestitures of Medical Imaging; Zimmer and Mead Johnson; and acquisition of DuPont Pharmaceuticals; L’Oreal (a significant owner of Sanofi) on the Sanofi-Aventis merger; Guidant’s acquisition of CardioThoracic Systems and Cook (withdrawn); Sofamor Danek’s sale to Medtronic; Oratec’s sale to Smith & Nephew; Johnson & Johnson’s acquisitions of Mitek, Cordis and Neutrogena, and divestiture of Janssen Animal Health; Fujisawa’s sale of its multisource pharmaceutical business.

Mr. Huffines’ equity offering experience includes offerings for Baxalta, Q\1intiles, Thermo Electron, Ironwood, Celgene, Bristol-Myers, Mead Johnson, Wyeth, Mylan, Medco Health Solutions, Kinetic Concepts, Zimmer, Guidant, Sofamor Danek, Volcano, and Medtronic. Fixed income transaction experience includes offerings for Eli Lilly, Merck, Celgene, Amgen, Bristol Myers Squibb, Johnson & Johnson, Wyeth, Pfizer, Guidant, Baxter, Medco Health Solutions Thermo Electron, and Quest.

Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financings and advisory assignments for emerging growth companies. Mr. Huffines has an M.B.A. from the University of Virginia, where he received the faculty award for academic excellence. He has a B.A. from the University of North Carolina, where he majored in English and Economics. Mr. Huffines is married and has four children. His volunteer work includes The Brookings/Gates Global Health Innovative Financing Advisory Group, the Student Sponsor Partnership, a member of the Corporate Advisory Board at the Darden School, a member of the Entrepreneurial Committee at the University of North Carolina and serving as a board member of the Spence School and Solid Biosciences.